Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 50

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
022,473)Interest expense134,050 209,138 Interest income(156,621)(88,133)Other income (expense), net180,240 (611,878)Net loss$(4,378,307)$(6,755,356)

25

13.    SUBSEQUENT EVENTS

Nasdaq Listing

The Company has not been in compliance with the requirement in Nasdaq Listing Rule 5550(b) for continued listing on The Nasdaq Capital Market since August 2024. On March 25, 2025, the Company presented its multi-step plan for regaining compliance to the Nasdaq Hearing Panel, or the Panel. On April 9, 2025, the Company received a letter from Nasdaq informing it that the Panel determined to grant its request for an extension until August 12, 2025 to demonstrate compliance with Nasdaq Listing Rule 5550(b) by demonstrating compliance with either Nasdaq Listing Rule 5550(b)(1) or 5550(b)(2). Nasdaq Listing Rule 5550(b)(1) requires a company to maintain stockholders’ equity of at least $2.5 million (the "Stockholders’ Equity Rule"), and Nasdaq Listing Rule 5550(b)(2) requires a company to maintain a minimum market value of listed securities of $35.0 million (the “Minimum MVLS Rule”). A company will satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b) if it meets either the Stockholders’ Equity Rule or the Minimum MVLS Rule. On April 29, 2025, the Company submitted a modified multi-step plan for regaining compliance to the Panel (the “Plan”), which the Panel approved. The Company's Plan includes, among other things, increasing its stockholders’ equity by May 31, 2025 and increasing it further by July 15, 2025. The Panel’s determination to grant the Company's request for an extension is subject to certain conditions, including, among others, that the Company make progress in executing against its Plan by the dates specified in its Plan and that on or before August 12, 2025 (a) the Company publicly discloses transactions it undertook to increase its stockholders’ equity and provide an indication of its stockholders’ equity following such transactions, and (b) the Company provide the Panel with an update on its fundraising plans and income projections for the next 12 months. The Company intends to publicly disclose